Clexane

Leaflet accompanying the packaging: patient information

Clexane, 2000 IU (20 mg)/0.2 ml, solution for injection in pre-filled syringes
Clexane, 4000 IU (40 mg)/0.4 ml, solution for injection in pre-filled syringes
Clexane, 6000 IU (60 mg)/0.6 ml, solution for injection in pre-filled syringes
Clexane, 8000 IU (80 mg)/0.8 ml, solution for injection in pre-filled syringes
Clexane, 10,000 IU (100 mg)/1 ml, solution for injection in pre-filled syringes
Enoxaparin sodium

Read the leaflet carefully before using the medicine, as it contains important information for the patient.

• Keep this leaflet, you may need to read it again.
• In case of any doubts, consult a doctor, pharmacist, or nurse.
• This medicine has been prescribed specifically for you. Do not pass it on to others. The medicine may harm another person, even if their symptoms are the same.
• If the patient experiences any side effects, including any side effects not listed in this leaflet, they should tell their doctor or pharmacist. See section 4.

Table of contents of the leaflet

• 1. What is Clexane and what is it used for
• 2. Important information before using Clexane
• 3. How to use Clexane
• 4. Possible side effects
• 5. How to store Clexane
• 6. Contents of the packaging and other information

1. What is Clexane and what is it used for

Clexane contains the active substance enoxaparin sodium. It belongs to a group of medicines called low molecular weight heparins or LMWH.

How Clexane works

Clexane works in two ways:

• 1) It prevents the growth of existing blood clots. This helps the body to dissolve existing blood clots, making them no longer harmful.
• 2) It prevents the formation of new blood clots in the patient's blood.

What Clexane is used for

Clexane can be used for:

• Treating blood clots that are already present in the patient's blood.
• Preventing the formation of blood clots in the patient's blood in the following cases: before and after surgery, during a short-term illness when the patient will not be able to move for a period, in patients who have developed blood clots in the circulating blood due to cancer, to further prevent the formation of new blood clots
• Preventing the formation of blood clots in unstable angina (when insufficient blood is supplied to the heart muscle) or after a heart attack
• Preventing the formation of clots in dialysis tubes (used in people with severe kidney function disorders).

2. Important information before using Clexane

Do not use Clexane if:

• the patient is allergic to: enoxaparin sodium or any of the other ingredients of this medicine (listed in section 6) heparin or other low molecular weight heparins, such as nadroparin, tinzaparin, or dalteparin. Symptoms of an allergic reaction may include: rash, difficulty breathing or swallowing, swelling of the face, lips, tongue, mouth, throat, or eyes.
• the patient has had a reaction to heparin that caused a significant decrease in the number of blood cells responsible for blood clotting (platelets) in the last 100 days.
• there are antibodies against enoxaparin in the patient's blood.
• the patient has severe bleeding or a medical condition associated with an increased risk of bleeding, such as: stomach ulcers, recent brain or eye surgery, or recent hemorrhagic stroke.
• the patient is using Clexane to treat blood clots and a lumbar puncture or spinal or epidural anesthesia is planned within 24 hours: the patient should not use Clexane. In case of doubts, consult a doctor or pharmacist before starting Clexane.

Warnings and precautions

Clexane should not be exchanged with other low molecular weight heparins such as nadroparin, tinzaparin, or dalteparin. This is because they are not exactly the same, differ in activity, and have different instructions for use.
Before starting Clexane, consult a doctor or pharmacist if:

• the patient has ever had a reaction to heparin that caused a large decrease in the number of blood cells responsible for blood clotting (platelets)
• the patient has a heart valve replacement
• the patient has endocarditis (infection of the membrane lining the heart)
• the patient has stomach ulcers
• the patient has recently had a brain stroke
• the patient has high blood pressure
• the patient has diabetes or has problems with blood vessels in the eyes caused by diabetes (so-called diabetic retinopathy)
• the patient has recently had eye or brain surgery
• the patient is elderly (over 65 years), especially if they are over 75 years old
• the patient has kidney disease
• the patient has liver disease
• the patient is underweight or overweight
• the patient has an increased level of potassium in the blood (which can be checked with a blood test)
• the patient is currently taking medications that may cause bleeding (see section 2 "Clexane and other medicines")
• the patient has spinal problems or has had spinal surgery. If any of the above situations apply to the patient or the patient has doubts, consult a doctor or pharmacist before starting Clexane.

In the case of patients taking doses higher than 210 mg/day, this medicine contains more than 24 mg of sodium (the main component of table salt) per dose. This corresponds to 1.2% of the maximum recommended daily intake of sodium in the diet for adults.

Tests and monitoring

Before starting this medicine and periodically during its use, the patient may undergo a blood test to check the number of platelets responsible for blood clotting and potassium levels in the blood.

Use in children and adolescents

The safety and efficacy of Clexane have not been evaluated in children and adolescents.

Clexane and other medicines

Tell the doctor or pharmacist about all medicines the patient is currently taking or has recently taken, as well as any medicines the patient plans to take.

• warfarin - a medicine used to thin the blood
• aspirin (also known as acetylsalicylic acid or ASA), clopidogrel, or other medicines used to prevent blood clots (see section 3 "Changing anticoagulant medicine")
• dextran injections - used as a blood substitute
• ibuprofen, diclofenac, ketorolac, or other non-steroidal anti-inflammatory medicines used to treat pain and swelling in arthritis and other conditions
• prednisolone, dexamethasone, or other medicines used to treat asthma, rheumatoid arthritis, and other conditions
• medicines that increase potassium levels in the blood, such as potassium salts, diuretics, or certain heart medicines

Surgical procedures and anesthetics

If the patient is scheduled for a lumbar puncture or surgery under spinal or epidural anesthesia, they should inform their doctor that they are taking Clexane.

Pregnancy and breastfeeding

If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult a doctor or pharmacist before using this medicine.
Women with pregnancy and mechanical heart valve may have an increased risk of blood clots. The doctor should discuss this with the patient.
Women who are breastfeeding or plan to breastfeed should consult a doctor before starting this medicine.

Driving and using machines

Clexane does not affect the ability to drive or use machines.
The doctor should document the trade name and batch number of the product used.

3. How to use Clexane

This medicine should always be used as directed by a doctor or pharmacist. In case of doubts, consult a doctor or pharmacist.

Taking the medicine

• Clexane will usually be administered to the patient by a doctor or nurse. This is because it requires injection.
• Clexane is usually administered subcutaneously.
• Clexane may be administered intravenously after certain types of heart attack or after surgery.
• Clexane may be introduced into the dialysis tube returning blood from the body (into the so-called arterial line) at the beginning of the dialysis session.
• Clexane must not be administered intramuscularly.

Dose

• The doctor will decide what dose of Clexane the patient should take. This depends on the reason for using the medicine.
• In the case of kidney disease, the patient may receive a lower dose of Clexane.
• 1) Treatment of blood clots in the patient's blood
• The usual dose is 150 IU (1.5 mg) per kilogram of body weight once daily or 100 IU (1 mg) per kilogram of body weight twice daily.
• The doctor will decide how long the patient should receive Clexane.
• 2) Prevention of blood clots in the patient's blood during surgery or during periods of reduced mobility due to illness
• The dose depends on the patient's risk of developing a blood clot. The patient will receive Clexane at a dose of 2000 IU (20 mg) or 4000 IU (40 mg) per day.
• In the case of planned surgery, the first injection is usually performed 2 hours or 12 hours before surgery.
• If the patient has reduced mobility due to illness, they will usually receive Clexane at a dose of 4000 IU (40 mg) per day.
• The doctor will decide how long the patient should receive Clexane.
• 3) Prevention of blood clots in patients with unstable angina or after a heart attack
• Clexane can be used in two different types of heart attacks.
• The dose of Clexane will depend on the patient's age and the type of heart attack that occurred.

Non-ST-segment elevation myocardial infarction (NSTEMI):

• The usual dose is 100 IU (1 mg) per kilogram of body weight every 12 hours.
• The doctor will usually recommend that the patient also take aspirin (acetylsalicylic acid).
• The doctor will decide how long the patient should receive Clexane.

ST-segment elevation myocardial infarction (STEMI) in patients under 75 years of age:

• The initial dose of Clexane is 3000 IU (30 mg) administered intravenously.
• Clexane is also administered subcutaneously. The usual dose is 100 IU (1 mg) per kilogram of body weight every 12 hours.
• The doctor will usually recommend that the patient also take aspirin (acetylsalicylic acid).
• The doctor will decide how long the patient should receive Clexane.

STEMI in patients 75 years of age or older:

• The usual dose is 75 IU (0.75 mg) per kilogram of body weight every 12 hours.
• The maximum amount of Clexane in the first two doses is 7500 IU (75 mg).
• The doctor will decide how long the patient should receive Clexane.

Patients undergoing percutaneous coronary intervention (PCI):

• Depending on when the last dose of Clexane was administered, the doctor may decide to administer an additional dose of Clexane before the PCI procedure. The medicine will be administered intravenously.
• 4) Prevention of blood clots in dialysis tubes
• The usual dose is 100 IU (1 mg) per kilogram of body weight.
• Clexane is injected into the dialysis tube returning blood from the body (into the so-called arterial line) at the beginning of the dialysis session. This amount usually lasts for a 4-hour dialysis session. However, if necessary, the doctor may administer an additional dose of 50 IU to 100 IU (0.5 to 1 mg) per kilogram of body weight.

Self-administration of Clexane.
If the patient is able to self-administer Clexane, the doctor or nurse will demonstrate how to do it. Do not attempt to self-administer if the patient has not been trained. In case of doubts, consult a doctor or nurse immediately. Administering the injection correctly under the skin (so-called subcutaneous injection) can reduce pain and bruising at the injection site.

Before self-administering Clexane

• Prepare all necessary items: syringe, alcohol swab, soap and water, and a container for medical waste.
• Check the expiration date on the packaging. Do not use the medicine after the expiration date.
• Check if the syringe is damaged and if the liquid is clear. If not, use another syringe.
• Make sure what dose is to be administered.
• Examine the abdomen to check if the last injection did not cause redness, skin color change, swelling, discharge, or if it is still painful. If so, consult a doctor or nurse.

Instructions for self-administering Clexane: (Instructions for pre-filled syringes without a safety system)

Preparing the injection site

• 1) Choose an injection site on the right or left side of the abdomen. The injection site should be at least 5 cm away from the navel towards the sides.
• Do not inject within 5 cm of the navel or around existing scars or bruises.
• Change the injection site between the left and right side of the abdomen, depending on the site of the previous injection.

• 2) Wash your hands. Clean the injection site with an alcohol swab or soap and water.
• 3) Sit or lie down in a comfortable position, so that you are relaxed. Make sure the injection site is in your field of vision. A chair, couch, or bed with pillows for support will be suitable.

Choosing the dose

• 1) Carefully remove the needle cap from the syringe. Discard the cap.
• Do not press the plunger before administering the injection to remove air bubbles. This may reduce the administered dose.
• After removing the cap, do not touch the needle. This will ensure the sterility of the needle.

• 2) If the amount of medicine in the syringe is consistent with the prescribed dose, there is no need to adjust the dose. You can now administer the injection.
• 3) If the dose depends on body weight, it may be necessary to adjust the dose in the syringe according to the prescribed dose. In this case, remove the excess medicine by holding the syringe upside down (to keep air bubbles in the syringe) and discard the excess medicine into a container.
• 4) A drop may appear at the end of the needle. If so, remove the drop before administering the injection by tapping the syringe with the needle facing down. You can now administer the injection.

Administering the injection

• 1) Hold the syringe in the hand you write with (like a pencil). With your other hand, gently grasp the cleaned skin of the abdomen with your index finger and thumb, creating a skin fold between your fingers.
• Make sure to maintain the skin fold during the injection.
• 2) Hold the syringe with the needle facing down (perpendicularly at a 90-degree angle). Insert the entire length of the needle into the skin fold.

• 3) Press the plunger with your thumb. This will introduce the medicine into the abdominal fat tissue. Administer the entire amount of medicine from the syringe.
• 4) Remove the needle from the injection site, pulling it straight out. Keep the needle away from yourself and others. Now you can release the skin fold.

After administering the injection

• 1) To avoid bruising, do not rub the injection site after administering the injection.
• 2) Dispose of the used syringe in a container for medical waste. Close the container and store it in a place that is not visible and inaccessible to children. If the container is full, dispose of it according to the doctor's or pharmacist's instructions.

Dispose of any unused medicines or waste in accordance with local regulations.
(Instructions for pre-filled syringes with a safety system of the ERIS type)

Preparing the injection site

• 1) Choose an injection site on the right or left side of the abdomen. The injection site should be at least 5 cm away from the navel towards the sides.
• Do not inject within 5 cm of the navel or around existing scars or bruises.
• Change the injection site between the left and right side of the abdomen, depending on the site of the previous injection.

• 2) Wash your hands. Clean the injection site with an alcohol swab or soap and water.
• 3) Sit or lie down in a comfortable position, so that you are relaxed. Make sure the injection site is in your field of vision. A chair, couch, or bed with pillows for support will be suitable.

Choosing the dose

• 1) Carefully remove the needle cap from the syringe. Discard the cap.
• Do not press the plunger before administering the injection to remove air bubbles. This may reduce the administered dose.
• After removing the cap, do not touch the needle. This will ensure the sterility of the needle.

• 2) If the amount of medicine in the syringe is consistent with the prescribed dose, there is no need to adjust the dose. You can now administer the injection.
• 3) If the dose depends on body weight, it may be necessary to adjust the dose in the syringe according to the prescribed dose. In this case, remove the excess medicine by holding the syringe upside down (to keep air bubbles in the syringe) and discard the excess medicine into a container.
• 4) A drop may appear at the end of the needle. If so, remove the drop before administering the injection by tapping the syringe with the needle facing down. You can now administer the injection.

Administering the injection

• 1) Hold the syringe in the hand you write with (like a pencil). With your other hand, gently grasp the cleaned skin of the abdomen with your index finger and thumb, creating a skin fold between your fingers.
• Make sure to maintain the skin fold during the injection.
• 2) Hold the syringe with the needle facing down (perpendicularly at a 90-degree angle). Insert the entire length of the needle into the skin fold.

• 3) Press the plunger with your thumb. This will introduce the medicine into the abdominal fat tissue. Administer the entire amount of medicine from the syringe.
• 4) Remove the needle from the injection site, pulling it straight out. The protective cap will automatically cover the needle. Now you can release the skin fold.

After administering the injection

• 1) To avoid bruising, do not rub the injection site after administering the injection.
• 2) Dispose of the used syringe in a container for medical waste. Close the container and store it in a place that is not visible and inaccessible to children. If the container is full, dispose of it according to the doctor's or pharmacist's instructions.

Dispose of any unused medicines or waste in accordance with local regulations.
(Instructions for pre-filled syringes with a safety system of the PREVENTIS type)

Preparing the injection site

• 1) Choose an injection site on the right or left side of the abdomen. The injection site should be at least 5 cm away from the navel towards the sides.
• Do not inject within 5 cm of the navel or around existing scars or bruises.
• Change the injection site between the left and right side of the abdomen, depending on the site of the previous injection.

• 2) Wash your hands. Clean the injection site with an alcohol swab or soap and water.
• 3) Sit or lie down in a comfortable position, so that you are relaxed. Make sure the injection site is in your field of vision. A chair, couch, or bed with pillows for support will be suitable.

Choosing the dose

• 1) Carefully remove the needle cap from the syringe. Discard the cap.
• Do not press the plunger before administering the injection to remove air bubbles. This may reduce the administered dose.
• After removing the cap, do not touch the needle. This will ensure the sterility of the needle.

• 2) If the amount of medicine in the syringe is consistent with the prescribed dose, there is no need to adjust the dose. You can now administer the injection.
• 3) If the dose depends on body weight, it may be necessary to adjust the dose in the syringe according to the prescribed dose. In this case, remove the excess medicine by holding the syringe upside down (to keep air bubbles in the syringe) and discard the excess medicine into a container.
• 4) A drop may appear at the end of the needle. If so, remove the drop before administering the injection by tapping the syringe with the needle facing down. You can now administer the injection.

Administering the injection

• 1) Hold the syringe in the hand you write with (like a pencil). With your other hand, gently grasp the cleaned skin of the abdomen with your index finger and thumb, creating a skin fold between your fingers.
• Make sure to maintain the skin fold during the injection.
• 2) Hold the syringe with the needle facing down (perpendicularly at a 90-degree angle). Insert the entire length of the needle into the skin fold.

• 3) Press the plunger with your thumb. This will introduce the medicine into the abdominal fat tissue. Administer the entire amount of medicine from the syringe.
• 4) Remove the needle from the injection site, pulling it straight out while keeping your fingers on the plunger. Hold the needle away from yourself and others, then firmly press the plunger to activate the safety system. The protective cap will automatically cover the needle. A audible "click" will confirm the activation of the protective cap. Now you can release the skin fold.

After administering the injection

• 1) To avoid bruising, do not rub the injection site after administering the injection.
• 2) Dispose of the used syringe in a container for medical waste. Close the container and store it in a place that is not visible and inaccessible to children. If the container is full, dispose of it according to the doctor's or pharmacist's instructions. Dispose of any unused medicines or waste in accordance with local regulations.

Changing anticoagulant medicine

• Changing Clexane to blood-thinning medicines called vitamin K antagonists (such as warfarin)The doctor will recommend that the patient undergo blood tests to determine the INR ratio and inform the patient when to stop taking Clexane.
• Changing vitamin K antagonist medicines (such as warfarin) to ClexaneStop taking the vitamin K antagonist medicine. The doctor will recommend that the patient undergo blood tests to determine the INR ratio and inform the patient when to start taking Clexane.
• Changing Clexane to direct oral anticoagulantsStop taking Clexane. Then start taking the direct oral anticoagulant 0 to 2 hours before the scheduled time of the next injection; and then continue taking the medicine as usual.
• Changing direct oral anticoagulant to ClexaneStop taking the direct oral anticoagulant. Clexane treatment can be started 12 hours after the last dose of the direct oral anticoagulant.

Using more than the recommended dose of Clexane

If the patient thinks they have used too much or too little Clexane, they should immediately inform their doctor, pharmacist, or nurse, even if they do not notice any problems. In case of accidental injection or ingestion of Clexane by a child, immediately go to the hospital emergency department.

Missing a dose of Clexane

If a dose is missed, take it as soon as possible. Do not take a double dose to make up for the missed dose. Keeping a diary helps to ensure that no dose is missed.

Stopping Clexane

It is important to continue administering Clexane injections until the doctor recommends stopping them. If treatment is stopped, a blood clot may form, which can be very dangerous.
In case of any further doubts about using this medicine, consult a doctor, pharmacist, or nurse.

4. Possible side effects

Like all medicines, Clexane can cause side effects, although not everybody gets them.

Severe side effects

Stop using Clexane and immediately consult a doctor or

nurseif the patient experiences symptoms of a severe allergic reaction (such as rash, difficulty breathing or swallowing, swelling of the face, lips, tongue, mouth, throat, or eyes).
In case of any of the following symptoms, stop using enoxaparin and seek medical attention immediately:

• Red, scaly, widespread rash with thickening under the skin and blisters, accompanied by fever. Symptoms usually appear at the beginning of treatment (acute generalized exanthematous pustulosis).

Like other similar medicines (used to reduce blood clotting), Clexane may cause bleeding. This can be life-threatening. In some cases, bleeding may not be immediately visible.

Immediately consult a doctor if:

• the patient experiences any bleeding that does not stop on its own
• the patient experiences signs of excessive bleeding such as weakness, fatigue, paleness, dizziness with headaches, or swelling of unknown origin. The doctor may decide to subject the patient to closer monitoring or change the medicine.

Immediately consult a doctor:

• if the patient experiences any signs of a blood clot, such as: crampy pain, redness, increased warmth, or swelling in one of the lower limbs - these are symptoms of deep vein thrombosis, shortness of breath, chest pain, fainting, or coughing up blood - these are symptoms of pulmonary embolism
• if the patient experiences a painful rash or dark red spots under the skin that do not disappear when pressed. The doctor may order blood tests to check the platelet count.

Other side effects:

Very common(may affect more than 1 in 10 people):

• bleeding
• increased activity of liver enzymes.

Common(may affect up to 1 in 10 people):

• increased tendency to bruise - this may be due to a decrease in platelet count
• pink spots on the skin - these changes are more likely at the injection sites of Clexane
• skin rash (hives)
• itching, red skin
• bruising or pain at the injection site
• decreased red blood cell count
• increased platelet count
• headaches.

Uncommon(may affect up to 1 in 100 people):

• sudden severe headache - this may be a sign of bleeding into the brain
• tenderness and swelling in the stomach - this may be a sign of bleeding into the stomach.
• large, red skin changes with an irregular shape, with blisters or without blisters
• skin irritation (local irritation)
• the patient may notice yellowing of the skin or eyes and darker urine. This may indicate liver disease.

Rare(may affect up to 1 in 1000 people):

• severe allergic reaction - symptoms of such a reaction may include: rash, difficulty swallowing or breathing, swelling of the lips, face, throat, or tongue
• increased potassium levels in the blood - this is more likely in people with kidney disease or diabetes. The doctor can check this with a blood test
• increased eosinophil count in the blood - the doctor can check this with a blood test
• hair loss
• osteoporosis (a condition in which bones are more prone to fractures) after long-term use of the medicine
• tingling, numbness, and weakness of the muscles (especially in the lower part of the body) after a lumbar puncture or spinal or epidural anesthesia
• loss of control over the bladder or bowel (a condition in which the patient is unable to control when they need to go to the toilet)
• hardening or a lump at the injection site.

Reporting side effects

If side effects occur, including any side effects not listed in this leaflet, tell the doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Drug Safety Monitoring, Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych, Al. Jerozolimskie 181C, 02-222 Warszawa.
Tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder or its representative in Poland.
Reporting side effects will help to gather more information on the safety of this medicine.

5. How to store Clexane

Do not store above 25°C. Do not freeze.
Store the medicine in a place that is not visible and inaccessible to children.
Do not use this medicine after the expiration date stated on the packaging. The expiration date refers to the last day of the specified month.
Do not use this medicine if the syringe is cracked, there are solid particles in the solution, or the solution has an abnormal color (see "What Clexane looks like and what the pack contains").
Medicines should not be disposed of via wastewater or household waste. Ask the pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.

6. Contents of the packaging and other information

What Clexane contains

• The active substance of Clexane is enoxaparin sodium.
• Each ml contains 100 mg of enoxaparin sodium, which corresponds to 10,000 IU of anti-Xa activity. Each pre-filled syringe of 0.2 ml contains 2000 IU (20 mg) of enoxaparin sodium. Each pre-filled syringe of 0.4 ml contains 4000 IU (40 mg) of enoxaparin sodium. Each pre-filled syringe of 0.6 ml contains 6000 IU (60 mg) of enoxaparin sodium. Each pre-filled syringe of 0.8 ml contains 8000 IU (80 mg) of enoxaparin sodium. Each pre-filled syringe of 1 ml contains 10,000 IU (100 mg) of enoxaparin sodium.
• The other ingredient is water for injections.

What Clexane looks like and what the pack contains

Clexane is a clear, colorless or yellowish solution for injection in a glass pre-filled syringe (with or without an automatic safety system).
Pack sizes: 2, 5, 6, 10, 12, 20, 24, 30, 50, 100 pre-filled syringes and in bulk packs of 3 x 10, 9 x 10, 100 x 10, and 200 x 10 pre-filled syringes.
Not all pack sizes may be marketed.

Marketing authorization holder

Sanofi Winthrop Industrie
82, Avenue Raspail
94250 Gentilly
France

Manufacturer

Sanofi Winthrop Industrie
Boulevard Industriel, zone industrielle
76580 Le Trait
France
Sanofi Winthrop Industrie
180, rue Jean Jaurès
94 700 Maisons-Alfort
France
CHINOIN Pharmaceutical and Chemical Works Private Co. Ltd.
Csanyikvölgy Site
Miszkolc, Csanyikvölgy
H-3510
Hungary
Sanofi-Aventis Private Co. Ltd
Budapest Logistics and Distribution Platform
Bdg. DC5, Campona utca1.
Budapest, 1225
Hungary
Sanofi-Aventis GmbH
Turm A, 29. OG, Wienerbergstraße 11
1100 Vienna
Austria
Sanofi-Aventis Deutschland GmbH
Industriepark Höchst-Brüningstraße 50
65926 Frankfurt am Main
Germany

To obtain more detailed information about the medicine and its names in the Member States of the European Economic Area, contact the representative of the marketing authorization holder in Poland:

Sanofi Sp. z o.o.
ul. Marcina Kasprzaka 6
01-211 Warszawa
tel.: +48 22 280 00 00

Date of last revision of the leaflet:

Other sources of information

Detailed information about this medicine is available on the website of the Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych (www.urpl.gov.pl)